Targeting Cancer

« All News Items

CollabRx apps discussed in the British Journal of Healthcare Computing

Posted in CollabRx News, Publications, Targeted Therapy Finder, Targeting Cancer by Ben Kaplan on June 21, 2012 | No Comments »

June 20, 2012 – 

The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy Finder – Colorectal Cancer app is a novel and much needed educational resource that provides cancer patients and physicians access to complex and highly valuable information about how tumour genetics can be used to guide through clinical trials and treatment options. This is one of the first sites which uses a cutting-edge approach for biomarker driven chemotherapy.”

First Success of Targeted Therapy in Most Common Genetic Subtype of Non-Small Cell Lung Cancer

Posted in Targeting Cancer by Ben Kaplan on May 31, 2012 | No Comments »

May 31, 2012 – 

A novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study involved 87 non-small cell lung cancer (NSCLC) patients whose tumors carry a mutation in the gene KRAS. Such tumors account for about 20 percent of NSCLC cases, but no targeted therapy has proved effective against them in previous clinical research. The drug under investigation, selumetinib, doesn’t attack KRAS directly, but interferes with one of its molecular henchmen, a protein called MEK. By many measures the group receiving selumetinib did significantly better than the control group.

GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma

Posted in Targeting Cancer by Ben Kaplan on May 29, 2012 | No Comments »

May 29, 2012 – 

London UK – GlaxoSmithKline plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patients with BRAF mutation-positive metastatic cutaneous melanoma. continue reading »

Researchers Create New Anti-cancer Drug Innovative Computer Modeling Techniques Utilized in Drug Development

Posted in Targeting Cancer by Ben Kaplan on May 29, 2012 | No Comments »

May 21, 2012 – 

HONOLULU- A team of University of Hawaii Cancer Center scientists have created a new type of anti-cancer drug, named BP-1-102 that targets a key protein that triggers the development of many types of cancer including lung, breast, and skin cancers. The development of BP-1-102 was guided by the research teams computer based molecular analysis of the cancer causing Stat 3 protein that causes cancer by promoting abnormal cell growth in otherwise healthy cells. continue reading »

World’s Largest Release Of Comprehensive Human Cancer Genome Data Helps Researchers Everywhere Speed Discoveries Whole genome data from hundreds of St. Jude Children’s Research Hospital patients exceeds volume of all other sources combined

Posted in Targeting Cancer by Ben Kaplan on May 29, 2012 | No Comments »

May 29, 2012 – 

MEMPHIS, Tenn. — To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease. The release of this data was announced as a part of a perspective published in Nature Genetics online May 29.